BPC-157 Dosage Guide: Complete Protocol for Recovery

BPC-157 (Body Protection Compound-157) is a stable synthetic pentadecapeptide — a 15-amino-acid fragment derived from a protein found in human gastric juice. That gastric origin is why it is unusually stable: it survives stomach acid and digestive enzymes that would shred most peptides, which is also why an oral form exists at all.

Mechanistically, research studies show BPC-157 upregulates angiogenesis (VEGF receptor signaling — new blood vessel growth), accelerates fibroblast migration and collagen synthesis, and supports tendon-to-bone healing. It also has a well-documented protective effect on the gut lining in animal models — including against NSAID-induced damage. Those three properties (blood supply, tissue building, gut repair) explain why nearly every BPC-157 study focuses on injury recovery.

Three rules define essentially every BPC-157 protocol: microgram doses scaled to body weight, twice-daily frequency, and defined cycles. BPC-157 has a short plasma half-life (measured in minutes to hours), but the downstream growth-factor effects persist much longer — hence twice-daily injections are the research convention rather than one large daily dose.

• •Dose scale: ~3.5 mcg per kg of body weight per administration, clamped to the standard research range of 250–500 mcg per dose.
• •Frequency: 2x daily (morning and evening) — the short half-life means steady coverage needs two administrations.
• •Route: subcutaneous injection near (but never into) the injury site for musculoskeletal use; oral capsules for gut-focused protocols.
• •Cycle: 4 weeks on, 4 weeks off is the standard research cycle.

The weight-based rule: 3.5 mcg/kg per administration, rounded to a practical syringe reading and kept inside the 250–500 mcg range the database uses. For most adults this lands between 250 and 350 mcg per dose.

Two honest observations from the research literature: below ~150 mcg per dose the animal-model extrapolation suggests effects taper quickly, and above ~500 mcg there is no evidence of added benefit — the angiogenesis and growth-factor pathways saturate. More is not better; consistency is. The protocol builder computes your exact dose from your weight automatically.

The dose scale barely changes — but route, cycle length, and stack decisions do:

The "near the injury site" convention: inject subcutaneously into the skin a few centimeters around the injured area — never into the tendon, joint capsule, or wound itself. Local delivery to the surrounding tissue is the whole point of the regional dosing seen in animal studies.

Even though BPC-157 is well tolerated in research reports, first cycles should ramp — it makes any reaction identifiable and attributable:

• •Week 1 — 250 mcg 2x daily subcutaneous. Fixed. No increases.
• •Week 2 — assess: appetite, energy, injection-site response, injury feel. If tolerated and progressing, move to your weight-based target dose (300–400 mcg 2x daily for most).
• •Weeks 3–4 — hold the target dose through the end of the cycle. Reassess the injury before extending.
• •Stubborn chronic injuries only — extend to 6 weeks maximum at the upper end (500 mcg 2x daily), then a mandatory 4-week break.

The standard research cycle is 4 weeks of use followed by a 4-week break. The break is not a formality: receptor and growth-factor pathway sensitivity, plus the chance to honestly re-evaluate whether the injury still needs support, both depend on it. Research protocols for chronic tendon damage sometimes run 6–8 week cycles, but any extension should come with a reason, not habit.

If a full 4-week cycle at a properly titrated dose produces no perceptible change in the injury, the answer is not a longer cycle or a bigger dose — it is a re-evaluation of the diagnosis. Tendon pain that is actually nerve entrapment will not respond to angiogenesis stimulation no matter how much you inject.

BPC-157 + TB-500 (thymosin beta-4 fragment) is the most popular recovery stack in the research community — the two cover complementary tissue-repair pathways and dose on different rhythms, so they interleave cleanly without competing for the same schedule. The full science is in the BPC-157 + TB-500 stack guide.

• •Morning: BPC-157 250–500 mcg subcutaneous near the injury site.
• •Evening: BPC-157 second dose.
• •Monday & Thursday: TB-500 2–2.5 mg subcutaneous anywhere (no need to align with BPC doses).
• •One stack change at a time — if you add TB-500 to an existing BPC cycle, keep the BPC dose constant for the first two weeks so any response is attributable.

Pre-blended BPC/TB vials (5 mg/5 mg or 10 mg/10 mg ratios) exist precisely for this stack — verify the blend ratio against your own dose math before switching from separate vials.

BPC-157 ships as a lyophilized powder, and every dosing decision flows from one division: peptide in the vial divided by water added. The classic 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL = 2,500 mcg/mL — so a 250 mcg dose is 10 units on an insulin syringe, and a 350 mcg dose is 14 units.

• •Full technique, storage windows, and worked examples: see the peptide reconstitution guide.
• •Instant math for any vial size and dose: the reconstitution calculator.
• •Injection-site technique, depth, and needle choice: the injection guide.

BPC-157 has a mild side-effect profile in research reports — which is precisely why it is worth listing what HAS been reported, so the rare events are recognizable:

• •Mild flushing or warmth shortly after injection (most common report; usually fades within minutes).
• •Injection-site irritation — redness or tenderness at the SC injection point. Rotate sites.
• •Dizziness (rare, typically transient).
• •Fatigue or mild lethargy reported occasionally at the start of a cycle; usually resolves within days.

What should stop a cycle immediately: any sign of allergic reaction (hives, swelling, breathing difficulty), infection at an injection site (spreading warmth, pus, streaking), or persistent unexplained symptoms. None of these are "push through" events.

• •Cancer or active tumor: BPC-157 is pro-angiogenic — it grows blood vessels, and tumors exploit exactly that pathway. An active cancer diagnosis is an absolute exclusion.
• •Warfarin / anticoagulants: animal studies suggest BPC-157 can modulate coagulation pathways. Combining with blood thinners is a bleeding-risk line you do not cross.
• •Pregnancy and breastfeeding: no data. Full stop.
• •Active bleeding or pre-surgical status: hold BPC-157 for 1–2 weeks before any planned surgery — the last thing you want around a surgical field is altered coagulation signaling.
• •Athletes under anti-doping jurisdiction: BPC-157 is on the WADA Prohibited List (S0, non-approved substances). A positive test is a real sanction, not a theoretical risk.
• •No FDA approval: every vial sold is sold for research use. Quality varies wildly between suppliers — third-party testing matters more with BPC-157 than with almost any other peptide because the market is huge.

For the full framework (interaction screening, sourcing, lab work, escalation rules), read the peptide safety guide — and run any planned stack through the protocol builder to screen against your conditions and medications before starting.